DOH exec identifies 5 medicines for compulsory price cut
The Department of Health (DOH) identified Tuesday five medicines that would be subjected to compulsory price cuts starting Aug. 15, 2009. The announcement came a day after President Gloria Macapagal Arroyo disclosed during her State of the Nation Address (SONA) that she placed "other" drugs under maximum retail price. Dr. Roberto So, head of health department's national drug program, said the medicines include two anti-cancer medications, and one each against high blood pressure, infection, and high cholesterol. âKung matatandaan natin, ang una nating inirekomenda sa opisina ng Pangulo ay 21 ibaât ibang klaseng gamot. Ngunit 16 sa mga ito boluntaryong ibinaba ng drug firms ang presyo, pero ang natirang lima hindi isinama sa pagbaba ng presyo sang-ayon sa inirekomenda natin sa EO," So said in an interview on dzBB radio. (We had recommended to the Office of the President 21 medicines to be placed under an executive order (EO) enforcing price cuts in accordance with the Cheaper Medicines Act. But drug makers have not voluntarily slashed prices of five medicines.) The five medicines to be placed under compulsory price cuts are: * Anti-cancer medications Doxorubicin with prices ranging P1465.75 to P2,265.74 and Cytarabine (P240 to P1,980); * Anti-high blood medications Amlodipine (P9.60 to P38.50); * Medication against common infection Azithromycin (P108.50 to P468.00); and * Anti-high cholesterol Atorvastatin (P34.45 to P91.79).